Business
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
SAN FRANCISCO, May 06, 2026--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the first quarter ended March 31, 2026.
About this update from Vir Biotechnology, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3057,"height":718,"url":"https://media.zenfs.com/en/business-wire.com/1bd374551dcce597d0c5832f46c59bc7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wqj0RrPv7cqCc6aTJEilWw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIyNQ--/https://media.zenfs.com/en/business-wire.com/1bd374551dcce597d0c5832f46c59bc7","width":960,"height":225},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/xJ2jhpBCsJnbhy_7e0NWwg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01NjQ-/https://media.zenfs.com/en/business-wire.com/1bd374551dcce597d0c5832f46c59bc7","width":1200,"height":282}},"lazy":false},{"type":"text","content":"- Global strategic collaboration with Astellas to advance PSMA-targeted, PRO-XTEN® dual-masked T-cell engager (TCE) VIR-5500 closed and first patient dosed in Phase 1 dose-expansion cohorts in patients with late-line metastatic prostate cancer","length":243,"tagName":"p"},{"type":"text","content":"- Company will present complete Week 96 Phase 2 SOLSTICE data on its combination regimen for chronic hepatitis delta (CHD) at the European Association for the Study of the Liver (EASL) Congress","length":193,"tagName":"p"},{"type":"text","content":"- Strong financial position with $809.3 million in cash and investments as of March 31, 2026, excluding $315 million combined Astellas upfront payment1 and equity investment to be received in the second quarter of 2026","length":218,"tagName":"p"},{"type":"text","content":"- Conference call scheduled for May 6, 2026, at 4:30 p.m. ET / 1:30 p.m. PT","length":75,"tagName":"p"},{"type":"text","content":"SAN FRANCISCO, May 06, 2026--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the first quarter ended March 31, 2026.","length":193,"tagName":"p"},{"type":"text","content":""Vir Bio delivered incredible momentum during the first quarter with positive, new VIR-5500 Phase 1 data and execution of a global agreement with Astellas in prostate cancer. The closing of our collaboration with Astellas in April has ignited the next stage of development work, bolstering our ability to move faster and think bigger together," said Marianne De Backer, Chief Executive Officer of Vir Biotechnology. "We also annou...